Across TCGA pan-cancer cohorts, SMTN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMTN data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SMTN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMTN expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where SMTN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.652	0.993	.001	10	view →
CCRCC	DFS	Tertile	III,IV	0.680	0.308	.047	2	view →
PDAC	DFS	Median	III,IV	0.451	0.263	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SMTN tumor-vs-normal RNA expression · all SMTN data types